Sort
15,273 grants matching “antimicrobial resistance”
Understanding the antimicrobial mechanism of metal nanoparticles using super resolution fluorescence microscopy
$498,983Yong Wang · University Of Arkansas · · FY2018 · ENG
T. vaginalis viruses as mucosal immunity modifiers with impact on women's health
$498,935Raina N Fichorova · Brigham And Women'S Hospital · RC1 · FY2010 · AI
Targeting hybrid histidine kinase for broad spectrum antifungal therapy
$498,908Bruce Steven Klein · University Of Wisconsin-Madison · RC1 · FY2009 · AI
Bacterial cell wall synthesis, shape and septation
$498,838Daniel E Voth · Univ Of Arkansas For Med Scis · R01 · FY2019 · GM
Development of an Oral Carbapenem Drug for Treatment of Drug Resistant TB
$498,800Gyanu Lamichhane · Johns Hopkins University · R33 · FY2016 · AI
Chicago Prevention and Intervention Epicenter II (CPIE-II)
$498,788Mary Katherine Hayden · Rush University Medical Center · U54 · FY2017 · CK
Pathobiology of heme inducible transporters in Gram positive pathogens
$498,638Eric P Skaar · Vanderbilt University Medical Center · R01 · FY2024 · AI
Pathobiology of heme inducible transporters in Gram positive pathogens
$498,638Eric P Skaar · Vanderbilt University Medical Center · R01 · FY2021 · AI
Peptide-mediated immunotherapy of KSHV-associated malignancy.
$498,591Jae U Jung · University Of Southern California · RC1 · FY2010 · CA
Pattern Recognition Receptors and Autophagy in Mtb Control in AIDS
$498,578Vojo P Deretic · University Of New Mexico · R01 · FY2012 · AI
ANti-infective Stewardship using the Wisca tool in the Electronic medical Record
$498,457Lance Robert Peterson · Endeavor Health Clinical Operations · R01 · FY2017 · HS
MASTITIS, DEFINED AS AN INFLAMMATION OF THE MAMMARY GLAND, IS THE MOST COMMON AND MOST ECONOMICALLY SIGNIFICANT DISEASE AFFECTING DAIRY CATTLE. IT IS THE LEADING CAUSE OF ANTIMICROBIAL USE ON DAIRY FARMS. STREPTOCOCCUS UBERIS (S. UBERIS) IS THE MOST PREVALENT GRM-POSITIVE ENVIRONMENTAL PATHOGEN ASSOCIATED WITH MASTITIS AND STRAIN 0140J IS CONSIDERED THE MOST VIRULENT. THE MAJORITY OF DISEASE (~70%) OCCURS AROUND THE TIME OF PARTURITION. CONTROL PRACTICES FOR MASTITIS, INCLUDING SANITARY REARING, HOUSING AND MILKING ENVIRONMENTS, AND TEAT DISINFECTION ARE LESS EFFECTIVE FOR CONTROLLING S. UBERIS-ASSOCIATED MASTITIS THAN OTHER MASTITIS PATHOGENS. AS A CONSEQUENCE, INTRAMAMMARY (IM) INFECTIONS CAUSED BY S. UBERIS ARE ESCALATING EVEN FOR WELL-MANAGED HERDS. STREPTOCOCCUS UBERIS -ASSOCIATED MASTITIS IS AN IMPORTANT ANIMAL WELFARE ISSUE BECAUSE OF THE SUFFERING IT CAUSES TO DAIRY COWS VIA A DECREASE MILK PRODUCTION AND FEED INTAKE, SWELLING OF THE UDDER, AND, IN EXTREME CASES, SEPTICEMIA ORENDOTOXEMIA CAUSED BY MASTITIS CAN RESULT IN DEATH. IT ALSO RESULTS IN VERY HIGH ECONOMIC LOSSES TO AFFECTED PRODUCERS EXCEEDING $2 BILLION PER YEAR COSTING APPROXIMATELY $179 PER CLINICAL CASE. GROWING CONSUMER CONCERNS REGARDING THE POTENTIAL FOR ANTIMICROBIAL RESISTANCE HAVE LED TO THE EXAMINATION OF ALTERNATIVE STRATEGIES FOR CONTROLLING MASTITIS WHILE REDUCING THE USE OF ANTIBIOTICS ON-FARM. THE STREPTOCOCCAL C1 PHAGE LYSIN, PLYC, IS THE MOST POTENT BACTERIOPHAGE ENDOLYSIN DESCRIBED TO DATE. THIS STUDY ADDRESSES THE USE OF A BACTERIOPHAGE ENZYME, PLYC, AS A NON-ANTIBIOTIC ALTERNATIVE THERAPY FOR THE TREATMENT OF S. UBERIS MASTITIS TO REDUCE USE OF ANTIBIOTICS, IMPROVE ANIMAL WELFARE AND ECONOMIC OUTCOME FOR PRODUCERS, MINIMIZE THE RISK OF ANTIBIOTIC RESIDUES IN MILK, AMELIORATE EFFECTIVENESS OF THERAPY WHEN USED IN COMBINATION WITH ON-FARM CULTURE SYSTEMS AND PROVIDE A NEW TREATMENT STRATEGY FOR CONVENTIONAL DAIRY PRODUCERS AS WELL AS ORGANICALLY MANAGED FARMS WHERE ANTIBIOTIC USAGE IS BANNED AND TREATMENT OPTIONS ARE LIMITED.THE SPECIFIC SCIENTIFIC OBJECTIVES OF THIS PROPOSAL ARE DESIGNED TO 1) EXAMINE THE USE OF PLYC, A BACTERIOPHAGE ENDOLYSIN, AS A NEW IM THERAPEUTIC FOR S. UBERIS MASTITIS IN LACTATING DAIRY COWS, 2) IDENTIFY APPROPRIATE WITHDRAWAL TIMES MILK FOR PLYC, AND 3) ELUCIDATE PRE-CLINICAL FACTORS SUCH AS THE BACTERIOLYTIC MECHANISM OF PLYC AGAINST S. UBERIS, ANTI-BIOFILM PROPERTIES AND RESISTANCE DEVELOPMENT. FOR OBJECTIVES 1 AND 2, THIRTEEN (N = 8 QUARTERS/TREATMENT; 25% REPLACEMENTS) HOLSTEIN-FRIESIAN LACTATING DAIRY COWS WILL BE INOCULATED 500 CFU OF S. UBERIS (STRAIN 0140J) INTO ALL FOUR MAMMARY QUARTERS. AFTER INFECTION IS ESTABLISHED, QUARTERS WITHIN COW (N = 8/TREATMENT) WILL BE RANDOMLY ASSIGNED TO RECEIVE 0, 62.5, 125 AND 250 MG OF PLYC OR CEFTIOFUR HYDROCHLORIDE (I.E. 125 MG X 10 ML VOLUME OF SPECTRAMAST® LC, ; A COMMON INTRAMAMMARY ANTIBIOTIC USED IN THE DAIRY INDUSTRY) ONCE DAILY FOR 3 CONSECUTIVE DAYS. ASEPTIC QUARTER FOREMILK SAMPLES WILL BE COLLECTED FOR 30 DAYS TO ASSESS CURE RATES. NUMBER OF CURES AND NUMBER OF CLEAR MILKINGS THAT A QUARTER REMAINED FREE OF S. UBERIS WILL BE RECORDED. FOR OBJECTIVE 3, THE MINIMAL BIOFILM ERADICATION CONCENTRATION, THE BIOMASS ERADICATION, THE MECHANISM OF PLYC ACTION AND THE DEVELOPMENT OF RESISTANCE WILL BE ASSESSED IN VITRO. THIS PROPOSAL INVOLVES THERAPEUTIC INTERVENTIONS FOR TREATMENT OF BOVINE MASTITIS EXAMINING NON-ANTIBIOTIC ALTERNATIVES.
$498,457University Of Maryland, College Park · · FY2018 · National Institute of Food and Agriculture
Southestern Pennsylvania Adult and Pediatric Prevention Epicenter Network
$498,350Ebbing Lautenbach · University Of Pennsylvania · U54 · FY2019 · CK
Southestern Pennsylvania Adult and Pediatric Prevention Epicenter Network
$498,350Ebbing Lautenbach · University Of Pennsylvania · U54 · FY2018 · CK
Reducing Antimicrobial Overuse in HCAP Through Personalized Antimicrobial Recommendations
$498,112Michael B Rothberg · Cleveland Clinic Foundation · R01 · FY2017 · HS
Multi-Drug Resistant Urinary Tract Infections in Ambulatory Settings
$497,946Ebbing Lautenbach · University Of Pennsylvania · R18 · FY2012 · HS
Development of RSK Inhibitors as Novel Therapeutics for Yersinia pestis
$497,899Jeffrey Smith · Luna Innovations, Inc. · R44 · FY2009 · AI
Containing Bioterroist and Emerging Infectious Diseases
$497,877Ira M Longini · Fred Hutchinson Cancer Research Center · U01 · FY2006 · GM
ANTIFUNGAL TREATMENTS ARE USED TO TREAT BOTH PLANTS AND PEOPLE WITH FUNGAL DISEASES, BUT FUNGAL RESISTANCE TO THESE TREATMENTS IS DEVELOPING IN BOTH THE CLINICAL AND AGRICULTURAL ENVIRONMENTS. APPROXIMATELY 200,000 LIFE-THREATENING CASES OF ASPERGILLOSIS IN PEOPLE, WHO ARE USUALLY IMMUNOCOMPROMISED, OCCUR ANNUALLY AND WITHOUT TREATMENT, OR WHEN THE FUNGUS IS RESISTANT, MORTALITY APPROACHES 100%. THE CAUSAL FUNGUS, ASPERGILLUS FUMIGATUS, IS UBIQUITOUS IN THE ENVIRONMENT, AND ABUNDANT IN SOIL, COMPOST AND OTHER ORGANIC DEBRIS. STUDIES OUTSIDE THE U.S. HAVE LINKED CLINICAL RESISTANCE TO INCREASED AGRICULTURAL USE OF AZOLE FUNGICIDES TO COMBAT PLANT PATHOGENS. RECENT RESEARCH HAS SHOWN THAT ANTIFUNGAL RESISTANT A. FUMIGATUS IS PRESENT IN AGRICULTURAL ENVIRONMENTS IN THE U.S. WHERE AZOLE FUNGICIDES ARE USED. THERE IS A CLEAR NEED FOR MONITORING OF AGRICULTURAL ENVIRONMENTS IN THE U.S. FOR ANTIFUNGAL-RESISTANT A. FUMIGATUS. WE AIM TO IMPROVE MOLECULAR DETECTION METHODS AND IDENTIFY AGRICULTURAL ENVIRONMENTS WITH INCREASED RATES OF AZOLE RESISTANCE TO ASSIST IN FORMULATING STRATEGIES TO SLOW THE DEVELOPMENT OF AZOLE RESISTANCE, AND TO IDENTIFY IF AZOLE-RESISTANT STRAINS ARE IN FOOD ITEMS PRODUCED WHERE RESISTANCE IS PREVALENT. ADDITIONALLY, WE PLAN TO DETERMINE IF POPULATIONS OF RESISTANT A. FUMIGATUS IN AGRICULTURAL ENVIRONMENTS DECLINE OR REMAIN STABLE IN THE ABSENCE OF AZOLE FUNGICIDE APPLICATIONS. THE GOAL OF THE PROPOSED RESEARCH IS TO BETTER UNDERSTAND THE DEVELOPMENT OF AZOLE RESISTANCE OF A. FUMIGATUS IN AGRICULTURAL ENVIRONMENTS SO THAT EFFICIENT AND TARGETED STRATEGIES AIMED AT MITIGATING ANTIMICROBIAL RESISTANCE CAN BE DEVELOPED, AND AZOLES CAN BE PRESERVED FOR USE IN TREATING HUMAN, ANIMAL AND PLANT DISEASES CAUSED BY FUNGI.
$497,816University Of Georgia Research Foundation, Inc. · · FY2019 · National Institute of Food and Agriculture
Improving Equitable Access to Penicillin Allergy De-Labeling
$497,778Alysse Gail Wurcel · Tufts Medical Center · R01 · FY2023 · HS
Integrated modeling of Klebsiella pneumoniae infections based on bacterial genotype, patient factors and colonization status
$497,708Michael Abbott Bachman · University Of Michigan At Ann Arbor · R01 · FY2018 · AI
The Impact of Healthcare Exposure on Colonization with Antiseptic Tolerant Staphylococci in Children
$497,655Jonathon Chase McNeil · Baylor College Of Medicine · R01 · FY2019 · HS
SBIR Phase II: Anti-Microbial Vinyl Nanocomposites
$497,589Andrew Myers · Tda Research, Inc · · FY2007 · TIP
Intestinal Enterococcal Dynamics: Modeling Host-Commensal and Host-Pathogen Interactions
$497,566Nita H Salzman · Medical College Of Wisconsin · R35 · FY2017 · GM
Integration of heme acquisition and signaling in Gram-negative pathogens
$497,496Angela None Wilks · University Of Maryland Baltimore · R01 · FY2021 · AI